Home › Drug Codes › J Codes › J8611 · Jylamvo
Updated October 1st, 2026

Jylamvo J Code: J8611

Methotrexate (jylamvo), oral, 2.5 mg

Login to unlock all benchmarks
Medicare Payment Limit ?
$18.264
up 10.9% since Q3 2026
/ HCPCS billing unitQ3 2026: $16.467
APC Payment Limit ?
$18.264
up 10.9% since Q3 2026
/ HCPCS billing unitQ3 2026: $16.467
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
1
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Methotrexate (jylamvo), oral, 2.5 mg
HCPCS Added Date July 1, 2024
Manufacturer Shorla Oncology
Route of Administration Oral
Generic Status Single-Source; Branded
Dosage Form Solution

About Jylamvo

Jylamvo is a medication aligned to the HCPCS J Code: J8611 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the oral route and manufactured by Shorla Oncology.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
81927-0204-01 Jylamvo SHORLA ONCOLOGY INC. 48 120 MG / 60 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

Jylamvo Pricing & Reimbursement

J8611 Private Payer Reimbursement
$19.05 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q4 2026

Methotrexate 505(b)(2) Information:

HCPCS Code Manufacturer Active Ingredient HCPCS Description
J8610 Generic Code (Multiple Manufacturers) Methotrexate Methotrexate; oral, 2.5 mg
J8611 Shorla Oncology Methotrexate Methotrexate (jylamvo), oral, 2.5 mg
J8612 Azurity Pharmaceuticals Methotrexate Methotrexate (xatmep), oral, 2.5 mg
Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Jylamvo Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute lymphoblastic leukemia Mycosis fungoides (cutaneous T-cell lymphoma) Polyarticular juvenile idiopathic arthritis Relapsed or refractory non-Hodgkin lymphomas Rheumatoid arthritis Severe psoriasis
Drug Class
Folate Analog Metabolic Inhibitor [EPC]Folic Acid Metabolism Inhibitors [MoA]

Try Pro free for 7 daysUpgrade to ProAdd Analytics and full history with ProComparative Report

Compare Jylamvo with same-ingredient drugs

  • Jylamvo J8611
  • METHOTREXATE J8610
  • METHOTREXATE J9260
  • Xatmep J8612
  • METHOTREXATE J9250

ASP, the Medicare payment limit, WAC and AWP for all 5 drugs on one timeline, with 10+ years of monthly history.

Card required · cancel anytime

Compare same-ingredient drugs →

Frequently Asked Questions

Is there an available Jylamvo billing and coding guide?
Our team has not identified a manufacturer-published source of billing and coding information for Jylamvo.
Are there any available Jylamvo patient assistance programs?
Jylamvo patient assistance information can be found through Shorla Oncology Inc.. Visit Here →
Where can I find Jylamvo prescribing information?
Jylamvo prescribing information can be found at the link below: Visit Here →
Where can I find Jylamvo side effect information?
Our team did not identify a source of side effect information for Jylamvo.
Does billing Jylamvo require JZ/JW wastage modifiers?
CMS does not include Jylamvo (J8611) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8611. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to Jylamvo.

J8610METHOTREXATEMethotrexate; oral, 2.5 mgMultiple ManufacturersAdded January 1, 1995J9260METHOTREXATEInjection, methotrexate sodium, 50 mgMultiple ManufacturersAdded January 1, 1984J8612XatmepMethotrexate (xatmep), oral, 2.5 mgAzurity PharmaceuticalsAdded July 1, 2024J9250METHOTREXATEMethotrexate sodium, 5 mgMultiple ManufacturersAdded January 1, 1994J0129ORENCIAInjection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)BMSAdded January 1, 2007J0717CIMZIAInjection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)UCB PharmaAdded January 1, 2014J1438ENBRELInjection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)AmgenAdded January 1, 2000J1602SIMPONI ARIAInjection, golimumab, 1 mg, for intravenous useJanssenAdded January 1, 2014J3262ACTEMRAInjection, tocilizumab, 1 mgMultiple ManufacturersAdded January 1, 2011J7509MEDROLMethylprednisolone oral, per 4 mgMultiple ManufacturersAdded January 1, 1996